IMMUNOPATHOGENESIS AND TREATMENT OF AUTOIMMUNE DISEASES: Edited by Cee s GM KallenbergThe interferon signature in autoimmune diseasesRönnblom, Lars; Eloranta, Maija-Leena Author Information Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden Correspondence to Professor, Lars Rönnblom, Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden. Tel: +46 18 6115398; fax: +46 18 500952; e-mail: [email protected] Current Opinion in Rheumatology 25(2):p 248-253, March 2013. | DOI: 10.1097/BOR.0b013e32835c7e32 Buy Metrics Abstract Purpose of review An increased expression of type I interferon (IFN) regulated genes (an IFN signature) has been reported in blood and tissue cells from patients with SLE and other autoimmune diseases. We review the possible mechanisms behind the IFN signature as well as clinical and therapeutic consequences of this observation. Recent findings Autoantigens from dying cells trigger plasmacytoid dendritic cells to a continuous synthesis of type I IFN, which is promoted by natural killer (NK) cells and B cells. A growing number of genes connected to type I IFN production and response associates with an increased susceptibility to autoimmunity. Besides type I IFN, type III IFN (IFN-λ) may contribute to the IFN signature. In SLE and primary Sjögren's syndrome, a prominent IFN signature is connected to an active disease, whereas in rheumatoid arthritis the IFN signature defines a disease subset with poor clinical outcome and treatment failure to B-cell depleting therapy. Several therapies aiming to inhibit the IFN signature are in clinical trials and early data suggest clinical benefits without major safety problems. Summary The observed IFN signature in several autoimmune diseases is a biomarker of active disease and is investigated as a tool when selecting treatment for individual patients. © 2013 Lippincott Williams & Wilkins, Inc.